Immunovaccine and Leidos are working together to determine the most promising malaria vaccine formulations.
Sanofi Pasteur has tapped Berg to learn more about biomarkers behind flu vaccine responses.
Here is some other vaccine news of note for this week.
Johnson & Johnson and a U.S. development agency are zeroing in on pandemic flu in a novel deal focusing on vaccine and flu drug candidates.
GSK has formed an alliance with China’s e-commerce giant Alibaba to help promote HPV vaccine Cervarix.
Merck KGaA’s MilliporeSigma and Baylor College of Medicine joined together to work on vaccines against neglected diseases.
Meissa Vaccines, a JLABS resident startup, has financial backing from the NIH and a VC firm to help advance its RSV vaccine candidate.
Valneva and Emergent BioSolutions will co-develop a Zika candidate slated to enter phase 1 in late 2017 or early 2018.
J&J's Janssen unit will shell out up to $879 million to develop HIV and HBV vaccines using Bavarian Nordic's MVA-BN technology.
Emergent BioSolutions has snapped up the only FDA-approved smallpox vaccine from Sanofi Pasteur.